Neuren Pharmaceuticals (ASX:NEU) received its one-third share of proceeds from Nasdaq-listed partner Acadia Pharmaceuticals' sale of the rare pediatric disease priority review voucher for $150 million in December 2024, according to a Friday filing with the Australian bourse.
The voucher was granted by the US Food and Drug Administration after the approval of Daybue for the treatment of Rett syndrome, the filing said.
Rett syndrome is a genetic disorder characterized by loss of mobility in the hands as development slows down.
The company is entitled to one-third of the proceeds under its license agreement with Acadia, per the filing.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。